Kopran Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹211 Cr +79.2% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
K

Kopran Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Kopran Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹135Cr
−3% YoY
−21.5% QoQ
Net profit
₹7Cr
−32.9% YoY
−23% QoQ
Margin
10.45%
−2.6 pp YoY
+0.5 pp QoQ

Kopran Ltd Q1 FY26 key numbers

Revenue
Year-on-year change in revenue: Slight decrease (Rs. 13,522 Lakhs vs Rs. 13,944 Lakhs).

As stated in Kopran Ltd's Q1 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Kopran Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹271
Market cap₹1.3K Cr
P/E53.7

The short version

Q1 FY 2025-26 revenue from operations: Rs. 13,522 Lakhs (Page 5). Q1 FY 2025-26 EBITDA: Rs. 1,413 Lakhs (Page 5).

From Kopran Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 FY 2025-26 revenue from operations: Rs. 13,522 Lakhs (Page 5)
  • Q1 FY 2024-25 revenue: Rs. 13,944 Lakhs (Page 5)
  • Year-on-year change in revenue: Slight decrease (Rs. 13,522 Lakhs vs Rs. 13,944 Lakhs)
  • Formulations Q1 FY 2025-26 revenue: Rs. 5,078 Lakhs; FY 2024-25 revenue: Rs. 26,249 Lakhs (Page 10)
  • APIs Q1 FY 2025-26 revenue: Rs. 8,303 Lakhs; FY 2024-25 revenue: Rs. 35,881 Lakhs (Page 8)

2 more points from Kopran Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Kopran Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Strategic imperatives (Page 15) mention capacity expansion and setting up an API and R&D facility at Panoli.
  • The focus is on capacity expansion to develop niche, high-value/high-volume APIs and intermediates.
  • Emphasis on compliance with global regulatory standards.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.

Kopran Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Kopran Ltd Q1 FY26 results — key figures

Kopran Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue135139-3%172-21.5%
Operating profit (EBITDA)1418-22.2%17-17.3%
Operating margin10.45%13.02%-2.6 pp9.92%+0.5 pp
Profit before tax1015-32.9%14-27.9%
Net profit (PAT)711-32.9%10-23%
EPS (₹)1.542.30-33%2.01-23.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Kopran Ltd Q1 FY26 results?

Q1 FY 2025-26 revenue from operations: Rs. 13,522 Lakhs (Page 5). Q1 FY 2025-26 EBITDA: Rs. 1,413 Lakhs (Page 5).

What is Kopran Ltd share price analysis?

Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.

Is Kopran Ltd planning capital expenditure?

Strategic imperatives (Page 15) mention capacity expansion and setting up an API and R&D facility at Panoli.

Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.